Ceribell Lifts 2026 Revenue Guidance After Record Account Adds

The Tip Desk · November 10, 2026 · 3 min read

Third-quarter revenue reached $29.3 million, up 30% from a year earlier, and the company raised full-year 2026 guidance to $115 million to $117 million.

Ceribell, Inc. (CBLL), a medical technology company focused on point-of-care electroencephalography for serious neurological conditions, reported third-quarter revenue of $29.3 million, a 30% increase from $22.6 million a year earlier, and raised its full-year 2026 revenue outlook to $115 million to $117 million.

The company said the update reflects continued momentum in its core seizure business from both new account additions and higher utilization in existing accounts. The new range implies growth of about 29% to 31% over prior-year revenue and does not include material contributions from neonate, pediatric, or delirium products.

Year-over-year revenue growth had been 33% in the second quarter and 29% in the first. Product revenue, the larger of the two lines, was $22.2 million, up 31% from $17.0 million a year earlier. Subscription revenue was $7.1 million, up 28% from $5.6 million, which the company attributed to continued growth in its installed base of Clarity subscriptions.

Ceribell ended the quarter with 747 active accounts, adding a record 35 net new customers. That compared with 712 accounts at the end of the second quarter and 680 at the end of the first. Co-founder and CEO Jane Chao, Ph.D., said the results reflected new highs in account additions and utilization within the existing account base.

Gross profit was $26.3 million, and gross margin was 90%, compared with 88% a year earlier. The company said margin strength was driven by manufacturing cost-reduction initiatives and a fully operational manufacturing line in Vietnam. The second-quarter margin of 92% had included one-time refunds of previously paid tariffs.

Operating expenses were $46.9 million, up 36% from $34.6 million a year earlier. The company said the increase was primarily attributable to continued investments in the commercial organization, including infrastructure in advance of the delirium launch, research and development for a next-generation hardware platform, algorithm development and clinical studies, stock-based compensation, and legal costs associated with intellectual property enforcement.

Net loss was $21.4 million, or $0.55 a share, compared with a net loss of $13.5 million, or $0.37 a share, a year earlier. Adjusted EBITDA loss was $12.1 million, compared with $9.2 million a year earlier.

The company announced the full launch of its delirium monitoring solution following a commercial pilot and received U.S. Food and Drug Administration 510(k) clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis. Chao said the full delirium launch and the coming introduction of a new hardware platform position the company for 2027.

Cash, cash equivalents, and marketable securities totaled $117.5 million as of September 30, 2026, down from $141.2 million as of March 31. In August, Ceribell entered a new credit facility providing access to up to $60 million in committed capital, comprising a $30 million term loan and a $30 million revolving credit facility, with an additional $25 million of uncommitted capital available at the lender’s discretion.